Reviva Pharmaceuticals

NASDAQ: RVPH Reviva Pharmaceuticals, Inc., (Reviva) headquartered in Santa Clara, California, is a publicly traded, late-stage clinical development pharmaceutical company. Reviva is developing a portfolio of internally discovered next generation innovative therapies using chemical genomic driven approaches and proprietary technologies that addresses unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic and inflammatory diseases. The leadership and management team is comprised of highly successful and experienced professionals from the pharmaceutical industry and have a demonstrated track record of taking drugs through the development process to the global market. Speed without sacrificing quality is one of the hallmarks of Reviva’s product development model. The company has a strong patent portfolio and promising multiple products in the pipeline at various stages of development. The company’s lead product RP5063 is a multimodal neuromodulator which has successfully completed the global Phase 2 clinical trials and has shown a superior efficacy and safety profile for schizophrenia and schizo affective disorder. After having a very successful End of Phase 2 ( EOP2 ) meeting with U.S. FDA, the company is now preparing to start the global Phase 3 clinical trials for RP5063 in acute and maintenance phase schizophrenia patients. The company is also planning to develop RP5063 for bipolar disorder, major depressive disorder (MDD), Alzheimer’s psychosis/agitation (ADP), Parkinson’s psychosis (PDP), attention deficit hyperactivity disorder (ADD/ADHD) and autism spectrum.